Guizhou Xinbang Pharmaceutical Co., Ltd.
Symbol: 002390.SZ
SHZ
3.89
CNYMarket price today
32.8887
P/E Ratio
-2.3022
PEG Ratio
7.06B
MRK Cap
- 0.01%
DIV Yield
Guizhou Xinbang Pharmaceutical Co., Ltd. (002390-SZ) Financial Statements
Balance Sheet
common:word.in-mln USD Growth | TTM | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | |||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
balance-sheet.row.cash-and-short-term-investments | 0 | 899.2 | 624.6 | 1776.4 | |||||||||||||||||
balance-sheet.row.short-term-investments | 0 | 0 | 0 | 0 | |||||||||||||||||
balance-sheet.row.net-receivables | 0 | 3870.6 | 4011.3 | 3466.8 | |||||||||||||||||
balance-sheet.row.inventory | 0 | 1032.7 | 935.7 | 843.4 | |||||||||||||||||
balance-sheet.row.other-current-assets | 0 | 3.7 | 4.7 | 4.6 | |||||||||||||||||
balance-sheet.row.total-current-assets | 0 | 5806.2 | 5576.4 | 6091.1 | |||||||||||||||||
balance-sheet.row.property-plant-equipment-net | 0 | 2671.7 | 2705.9 | 2323.2 | |||||||||||||||||
balance-sheet.row.goodwill | 0 | 607.3 | 607.3 | 605.5 | |||||||||||||||||
balance-sheet.row.intangible-assets | 0 | 204.4 | 217.6 | 219.6 | |||||||||||||||||
balance-sheet.row.goodwill-and-intangible-assets | 0 | 811.7 | 825 | 825.1 | |||||||||||||||||
balance-sheet.row.long-term-investments | 0 | 343.8 | 347.4 | 223 | |||||||||||||||||
balance-sheet.row.tax-assets | 0 | 62.4 | 55.6 | 46.5 | |||||||||||||||||
balance-sheet.row.other-non-current-assets | 0 | 97.2 | 118.4 | 153.2 | |||||||||||||||||
balance-sheet.row.total-non-current-assets | 0 | 3986.9 | 4052.3 | 3571 | |||||||||||||||||
balance-sheet.row.other-assets | 0 | 0 | 0 | 0 | |||||||||||||||||
balance-sheet.row.total-assets | 0 | 9793.1 | 9628.6 | 9662.2 | |||||||||||||||||
balance-sheet.row.account-payables | 0 | 977.2 | 993.4 | 788.6 | |||||||||||||||||
balance-sheet.row.short-term-debt | 0 | 1345.8 | 1362.3 | 3382.5 | |||||||||||||||||
balance-sheet.row.tax-payables | 0 | 33.3 | 37.4 | 32.2 | |||||||||||||||||
balance-sheet.row.long-term-debt-total | 0 | 22 | 24.8 | 24.5 | |||||||||||||||||
Deferred Revenue Non Current | 0 | 18.9 | 20.4 | 22.9 | |||||||||||||||||
balance-sheet.row.deferred-tax-liabilities-non-current | 0 | - | - | - | |||||||||||||||||
balance-sheet.row.other-current-liab | 0 | 330.6 | 6.5 | 4.6 | |||||||||||||||||
balance-sheet.row.total-non-current-liabilities | 0 | 41.2 | 45.5 | 23.2 | |||||||||||||||||
balance-sheet.row.other-liabilities | 0 | 0 | 0 | 0 | |||||||||||||||||
balance-sheet.row.capital-lease-obligations | 0 | 22 | 24.8 | 24.5 | |||||||||||||||||
balance-sheet.row.total-liab | 0 | 2728 | 2800.1 | 4493.7 | |||||||||||||||||
balance-sheet.row.preferred-stock | 0 | 0 | 0 | 0 | |||||||||||||||||
balance-sheet.row.common-stock | 0 | 1943.9 | 2027.2 | 1667.2 | |||||||||||||||||
balance-sheet.row.retained-earnings | 0 | 373.2 | 271.5 | 28 | |||||||||||||||||
balance-sheet.row.accumulated-other-comprehensive-income-loss | 0 | 189.6 | 102.7 | 57.3 | |||||||||||||||||
balance-sheet.row.other-total-stockholders-equity | 0 | 4301.7 | 4218.4 | 3165.9 | |||||||||||||||||
balance-sheet.row.total-stockholders-equity | 0 | 6808.5 | 6619.8 | 4918.3 | |||||||||||||||||
balance-sheet.row.total-liabilities-and-stockholders-equity | 0 | 9793.1 | 9628.6 | 9662.2 | |||||||||||||||||
balance-sheet.row.minority-interest | 0 | 256.6 | 208.7 | 250.2 | |||||||||||||||||
balance-sheet.row.total-equity | 0 | 7065 | 6828.5 | 5168.5 | |||||||||||||||||
balance-sheet.row.total-liabilities-and-total-equity | 0 | - | - | - | |||||||||||||||||
Total Investments | 0 | 343.8 | 347.4 | 223 | |||||||||||||||||
balance-sheet.row.total-debt | 0 | 1367.8 | 1387.1 | 3382.5 | |||||||||||||||||
balance-sheet.row.net-debt | 0 | 468.6 | 762.5 | 1606.1 |
Cash Flow Statement
common:word.in-mln USD Growth | TTM | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | |||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
cash-flows.row.net-income | 0 | 268.4 | 374 | 220.6 | |||||||||||||||||
cash-flows.row.depreciation-and-amortization | 0 | 243.5 | 247.3 | 231.6 | |||||||||||||||||
cash-flows.row.deferred-income-tax | 0 | -6.8 | -9.1 | 6.4 | |||||||||||||||||
cash-flows.row.stock-based-compensation | 0 | 31.5 | 6 | -6.4 | |||||||||||||||||
cash-flows.row.change-in-working-capital | 0 | -117.1 | -338.6 | 74.8 | |||||||||||||||||
cash-flows.row.account-receivables | 0 | 95 | -609.8 | 348.1 | |||||||||||||||||
cash-flows.row.inventory | 0 | -97 | -92.3 | 150.9 | |||||||||||||||||
cash-flows.row.account-payables | 0 | -108.3 | 372.6 | -430.6 | |||||||||||||||||
cash-flows.row.other-working-capital | 0 | -6.8 | -9.1 | 6.4 | |||||||||||||||||
cash-flows.row.other-non-cash-items | 0 | 171.3 | 178.4 | 215 | |||||||||||||||||
cash-flows.row.net-cash-provided-by-operating-activities | 0 | 0 | 0 | 0 | |||||||||||||||||
cash-flows.row.investments-in-property-plant-an-equipment | 0 | -158.8 | -253.8 | -138.1 | |||||||||||||||||
cash-flows.row.acquisitions-net | 0 | 1.6 | -295.5 | 566.1 | |||||||||||||||||
cash-flows.row.purchases-of-investments | 0 | -12.4 | -1719.6 | -1516.5 | |||||||||||||||||
cash-flows.row.sales-maturities-of-investments | 0 | 51 | 1523.6 | 1494.7 | |||||||||||||||||
cash-flows.row.other-investing-activites | 0 | 0.5 | 0.9 | 1.7 | |||||||||||||||||
cash-flows.row.net-cash-used-for-investing-activites | 0 | -118 | -744.3 | 408 | |||||||||||||||||
cash-flows.row.debt-repayment | 0 | -2019.5 | -4257 | -3561.4 | |||||||||||||||||
cash-flows.row.common-stock-issued | 0 | 0 | 0 | 86.2 | |||||||||||||||||
cash-flows.row.common-stock-repurchased | 0 | 0 | 0 | -86.2 | |||||||||||||||||
cash-flows.row.dividends-paid | 0 | -168.4 | -230.3 | -197.6 | |||||||||||||||||
cash-flows.row.other-financing-activites | 0 | 1998.4 | 3576.7 | 3171.8 | |||||||||||||||||
cash-flows.row.net-cash-used-provided-by-financing-activities | 0 | -189.4 | -910.6 | -587.2 | |||||||||||||||||
cash-flows.row.effect-of-forex-changes-on-cash | 0 | 0 | 0 | 2.3 | |||||||||||||||||
cash-flows.row.net-change-in-cash | 0 | 283.4 | -1196.9 | 565.2 | |||||||||||||||||
cash-flows.row.cash-at-end-of-period | 0 | 797 | 513.7 | 1710.6 | |||||||||||||||||
cash-flows.row.cash-at-beginning-of-period | 0 | 513.7 | 1710.6 | 1145.4 | |||||||||||||||||
cash-flows.row.operating-cash-flow | 0 | 590.8 | 458 | 742.1 | |||||||||||||||||
cash-flows.row.capital-expenditure | 0 | -158.8 | -253.8 | -138.1 | |||||||||||||||||
cash-flows.row.free-cash-flow | 0 | 432 | 204.2 | 604 |
Income Statement Row
common:word.in-mln USD Growth | TTM | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | |||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
income-statement-row.row.total-revenue | 0 | 6350 | 6471.9 | 5845.6 | |||||||||||||||||
income-statement-row.row.cost-of-revenue | 0 | 5133.1 | 5119.4 | 4593.5 | |||||||||||||||||
income-statement-row.row.gross-profit | 0 | 1217 | 1352.5 | 1252.1 | |||||||||||||||||
income-statement-row.row.gross-profit-ratio | 0 | 0 | 0 | 0 | |||||||||||||||||
income-statement-row.row.research-development | 0 | - | - | - | |||||||||||||||||
income-statement-row.row.selling-general-administrative | 0 | - | - | - | |||||||||||||||||
income-statement-row.row.selling-and-marketing-expenses | 0 | - | - | - | |||||||||||||||||
income-statement-row.row.other-expenses | 0 | 292 | 297.8 | 268.3 | |||||||||||||||||
income-statement-row.row.operating-expenses | 0 | 836.4 | 787.1 | 802.1 | |||||||||||||||||
income-statement-row.row.cost-and-expenses | 0 | 5969.5 | 5906.5 | 5395.7 | |||||||||||||||||
income-statement-row.row.interest-income | 0 | 13.5 | 14 | 15.4 | |||||||||||||||||
income-statement-row.row.interest-expense | 0 | 51.8 | 100.2 | 99.6 | |||||||||||||||||
income-statement-row.row.selling-and-marketing-expenses | 0 | - | - | - | |||||||||||||||||
income-statement-row.row.total-other-income-expensenet | 0 | -114.4 | -30.4 | -162.5 | |||||||||||||||||
income-statement-row.row.ebitda-ratio-caps | 0 | - | - | - | |||||||||||||||||
income-statement-row.row.other-operating-expenses | 0 | 292 | 297.8 | 268.3 | |||||||||||||||||
income-statement-row.row.total-operating-expenses | 0 | -114.4 | -30.4 | -162.5 | |||||||||||||||||
income-statement-row.row.interest-expense | 0 | 51.8 | 100.2 | 99.6 | |||||||||||||||||
income-statement-row.row.depreciation-and-amortization | 0 | 243.5 | 347.7 | 231.6 | |||||||||||||||||
income-statement-row.row.ebitda-caps | 0 | - | - | - | |||||||||||||||||
income-statement-row.row.operating-income | 0 | 427.8 | 451.5 | 429.9 | |||||||||||||||||
income-statement-row.row.income-before-tax | 0 | 313.4 | 421.1 | 267.5 | |||||||||||||||||
income-statement-row.row.income-tax-expense | 0 | 45 | 47.2 | 46.9 | |||||||||||||||||
income-statement-row.row.net-income | 0 | 224.5 | 374 | 173.5 |
Frequently Asked Question
What is Guizhou Xinbang Pharmaceutical Co., Ltd. (002390.SZ) total assets?
Guizhou Xinbang Pharmaceutical Co., Ltd. (002390.SZ) total assets is 9793091573.000.
What is enterprise annual revenue?
The annual revenue is N/A.
What is firm profit margin?
Firm profit margin is 0.190.
What is company free cash flow?
The free cash flow is 0.334.
What is enterprise net profit margin?
The net profit margin is 0.037.
What is firm total revenue?
The total revenue is 0.053.
What is Guizhou Xinbang Pharmaceutical Co., Ltd. (002390.SZ) net profit (net income)?
The net profit (net income) is 224479086.000.
What is firm total debt?
The total debt is 1367777175.000.
What is operating expences number?
The operating expences are 836448131.000.
What is company cash figure?
Enretprise cash is 0.000.